Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jose A Garcia-Saenz

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Future Oncology (London, England)|August 13, 2020
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancerMiguel Martin, Jose A Garcia-Saenz, Luis Manso, et al.
The Oncologist|April 7, 2021
In ReplyHope S Rugo, Jens Huober, Jose A Garcia-Saenz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2014
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancerCristina Saura, Jose A Garcia-Saenz, Binghe Xu, et al.
BMC Cancer|March 11, 2014
Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II studyThomas Bachelot, Jose A Garcia-Saenz, Sunil Verma, et al.
NPJ Breast Cancer|April 27, 2026
Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trialJoyce O'Shaughnessy, Francois-Clement Bidard, Patrick Neven, et al.
International Journal of Radiation Oncology, Biology, Physics|December 25, 2016
Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 StudyRicard Mesía, Jose A Garcia-Saenz, Alicia Lozano, et al.
Breast Cancer Research and Treatment|May 4, 2024
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohortRodrigo Sánchez-Bayona, Alfonso Lopez de Sa, Yolanda Jerez Gilarranz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2025
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA TrialFederico Rojo, Clive R Taylor, Carlos Barrios, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2025
Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast CancerMiguel Martín, Angel L Guerrero-Zotano, María E Pérez-López, et al.
Journal of the National Cancer Institute|August 10, 2020
Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line ChemotherapyMark Jesus M Magbanua, Laura H Hendrix, Terry Hyslop, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Future Oncology (London, England)|August 13, 2020
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancerMiguel Martin, Jose A Garcia-Saenz, Luis Manso, et al.
The Oncologist|April 7, 2021
In ReplyHope S Rugo, Jens Huober, Jose A Garcia-Saenz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2014
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancerCristina Saura, Jose A Garcia-Saenz, Binghe Xu, et al.
BMC Cancer|March 11, 2014
Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II studyThomas Bachelot, Jose A Garcia-Saenz, Sunil Verma, et al.
NPJ Breast Cancer|April 27, 2026
Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trialJoyce O'Shaughnessy, Francois-Clement Bidard, Patrick Neven, et al.
International Journal of Radiation Oncology, Biology, Physics|December 25, 2016
Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 StudyRicard Mesía, Jose A Garcia-Saenz, Alicia Lozano, et al.
Breast Cancer Research and Treatment|May 4, 2024
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohortRodrigo Sánchez-Bayona, Alfonso Lopez de Sa, Yolanda Jerez Gilarranz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2025
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA TrialFederico Rojo, Clive R Taylor, Carlos Barrios, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2025
Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast CancerMiguel Martín, Angel L Guerrero-Zotano, María E Pérez-López, et al.
Journal of the National Cancer Institute|August 10, 2020
Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line ChemotherapyMark Jesus M Magbanua, Laura H Hendrix, Terry Hyslop, et al.
Pageof 2